Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Ovarian Cancer | Research

Survival time prediction in patients with high-grade serous ovarian cancer based on 18F-FDG PET/CT- derived inter-tumor heterogeneity metrics

Authors: Dianning He, Xin Zhang, Zhihui Chang, Zhaoyu Liu, Beibei Li

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The presence of heterogeneity is a significant attribute within the context of ovarian cancer. This study aimed to assess the predictive accuracy of models utilizing quantitative 18F-FDG PET/CT derived inter-tumor heterogeneity metrics in determining progression-free survival (PFS) and overall survival (OS) in patients diagnosed with high-grade serous ovarian cancer (HGSOC). Additionally, the study investigated the potential correlation between model risk scores and the expression levels of p53 and Ki-67.

Methods

A total of 292 patients diagnosed with HGSOC were retrospectively enrolled at Shengjing Hospital of China Medical University (median age: 54 ± 9.4 years). Quantitative inter-tumor heterogeneity metrics were calculated based on conventional measurements and texture features of primary and metastatic lesions in 18F-FDG PET/CT. Conventional models, heterogeneity models, and integrated models were then constructed to predict PFS and OS. Spearman’s correlation coefficient (ρ) was used to evaluate the correlation between immunohistochemical scores of p53 and Ki-67 and model risk scores.

Results

The C-indices of the integrated models were the highest for both PFS and OS models. The C-indices of the training set and testing set of the integrated PFS model were 0.898 (95% confidence interval [CI]: 0.881–0.914) and 0.891 (95% CI: 0.860–0.921), respectively. For the integrated OS model, the C-indices of the training set and testing set were 0.894 (95% CI: 0.871–0.917) and 0.905 (95% CI: 0.873–0.936), respectively. The integrated PFS model showed the strongest correlation with the expression levels of p53 (ρ = 0.859, p < 0.001) and Ki-67 (ρ = 0.829, p < 0.001).

Conclusions

The models based on 18F-FDG PET/CT quantitative inter-tumor heterogeneity metrics exhibited good performance for predicting the PFS and OS of patients with HGSOC. p53 and Ki-67 expression levels were strongly correlated with the risk scores of the integrated predictive models.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed
3.
4.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668–79.CrossRefPubMedPubMedCentral
5.
Gao B, Zhao X, Gu P, Sun D, Liu X, Li W, Zhang A, Peng E, Xu D. A nomogram model based on clinical markers for predicting malignancy of ovarian tumors. Front Endocrinol (Lausanne). 2022;13: 963559.CrossRefPubMedPubMedCentral
6.
Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrere S, Quenet F, Gutowski M, Mourregot A, D’Hondt V, Coupier I, et al. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2020;12(8):2184.CrossRefPubMedPubMedCentral
7.
Lakis S, Kotoula V, Koliou GA, Efstratiou I, Chrisafi S, Papanikolaou A, Zebekakis P, Fountzilas G. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer. Cancer Genomics Proteomics. 2020;17(5):529–41.CrossRefPubMedPubMedCentral
8.
Nameki R, Chang H, Reddy J, Corona RI, Lawrenson K. Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. Pharmacol Ther. 2021;220: 107722.CrossRefPubMed
9.
Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, Gale D, Sayal K, Murtaza M, Baldwin PJ, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2): e1001789.CrossRefPubMedPubMedCentral
10.
McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016;48(7):758–67.CrossRefPubMed
11.
Fujita H. AI-based computer-aided diagnosis (AI-CAD): the latest review to read first. Radiol Phys Technol. 2020;13(1):6–19.CrossRefPubMed
12.
Nougaret S, Tibermacine H, Tardieu M, Sala E. Radiomics: an Introductory Guide to What It May Foretell. Curr Oncol Rep. 2019;21(8):70.CrossRefPubMed
13.
Fehr D, Veeraraghavan H, Wibmer A, Gondo T, Matsumoto K, Vargas HA, Sala E, Hricak H, Deasy JO. Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(46):E6265–6273.ADSPubMedPubMedCentral
14.
Rao SX, Lambregts DM, Schnerr RS, Beckers RC, Maas M, Albarello F, Riedl RG, Dejong CH, Martens MH, Heijnen LA, et al. CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy? United European Gastroenterol J. 2016;4(2):257–63.CrossRefPubMed
15.
Veeraraghavan H, Vargas HA, Sanchez A-J, Miccó M, Mema E, Capanu M, Zheng J, Lakhman Y, Crispin-Ortuzar M, Huang E, et al. Computed Tomography Measures of Inter-site tumor Heterogeneity for Classifying Outcomes in High-Grade Serous Ovarian Carcinoma: a Retrospective Study. BioRxiv. 2019;26:531046.
16.
Veeraraghavan H, Vargas HA, Sanchez AJ, Micco M, Mema E, Lakhman Y, Crispin-Ortuzar M, Huang EP, Levine DA, Grisham RN, et al. Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers (Basel). 2020;12(11):3403.CrossRefPubMed
17.
Himoto Y, Veeraraghavan H, Zheng J, Zamarin D, Snyder A, Capanu M, Nougaret S, Vargas HA, Shitano F, Callahan M, et al. Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer. JCO precision oncology. 2019;15:3.
18.
Ali AT, Al-ani O, Al-ani F. Epidemiology and risk factors for ovarian cancer. Menopausal Review. 2023;22(2):93–104.CrossRef
19.
Salvador S, Scott S, Glanc P, Eiriksson L, Jang J-H, Sebastianelli A, Dean E. Guideline No. 403: Initial Investigation and Management of Adnexal Masses. J Obstet Gynaecol Can. 2020;42(8):1021–1029.e1023.CrossRefPubMed
20.
Li X, Wang L, Guo P, Sun Q, Zhang Y, Chen C, Zhang Y. Diagnostic performance of noninvasive imaging using computed tomography, magnetic resonance imaging, and positron emission tomography for the detection of ovarian cancer: a meta-analysis. Annals of Nuclear Medicine. 2023;37(10):541–50.CrossRefPubMed
21.
Chung HH, Kang WJ, Kim JW, Park N-H, Song Y-S, Chung J-K, Kang S-B, Lee H-P. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. European Journal of Nuclear Medicine and Molecular Imaging. 2006;34(4):480–6.CrossRefPubMed
22.
Friedman SN, Itani M, Dehdashti F. PET Imaging for Gynecologic Malignancies. Radiol Clin North Am. 2021;59(5):813–33.CrossRefPubMed
23.
Daoud T, Sardana S, Stanietzky N, Klekers AR, Bhosale P, Morani AC. Recent Imaging Updates and Advances in Gynecologic Malignancies. Cancers. 2022;14(22):5528.CrossRefPubMedPubMedCentral
24.
Lopez-Lopez V, Cascales-Campos PA, Gil J, Frutos L, Andrade RJ, Fuster-Quiñonero M, Feliciangeli E, Gil E, Parrilla P. Use of 18 FFDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Eur J Radiol. 2016;85(10):1824–8.CrossRefPubMed
25.
Kemppainen J, Hynninen J, Virtanen J, Seppänen M. PET/CT for Evaluation of Ovarian Cancer. Seminars in Nuclear Medicine. 2019;49(6):484–92.CrossRefPubMed
26.
Delgado Bolton RC, Calapaquí Terán AK, Pellet O, Ferrero A, Giammarile F. The Search for New 2–18F-FDG PET/CT Imaging Biomarkers in Advanced Ovarian Cancer Patients. Clinical Nuclear Medicine. 2021;46(11):906–7.CrossRefPubMed
27.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
28.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nuclear Med Mol Imaging. 2014;42(2):328–54.CrossRef
29.
Hatt M, Krizsan AK, Rahmim A, Bradshaw TJ, Costa PF, Forgacs A, Seifert R, Zwanenburg A, El Naqa I, Kinahan PE, et al. Joint EANM/SNMMI guideline on radiomics in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging. 2022;50(2):352–75.CrossRefPubMedPubMedCentral
30.
Lin CN, Huang WS, Huang TH, Chen CY, Huang CY, Wang TY, Liao YS, Lee LW. Adding Value of MRI over CT in Predicting Peritoneal Cancer Index and Completeness of Cytoreduction. Diagnostics (Basel). 2021;11(4):5528.
31.
Stalberg K, Jonsdottir B. ASO Author Reflections: Use of Peritoneal Cancer Index (PCI) to Evaluate Carcinomatosis in Ovarian Cancer. Ann Surg Oncol. 2020;27(Suppl 3):763–4.CrossRefPubMedPubMedCentral
32.
Zwanenburg A, Vallieres M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020;295(2):328–38.CrossRefPubMed
33.
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019;76(4):469–78.CrossRefPubMedPubMedCentral
34.
Dogan S, Vasudevaraja V, Xu B, Serrano J, Ptashkin RN, Jung HJ, Chiang S, Jungbluth AA, Cohen MA, Ganly I, et al. DNA methylation-based classification of sinonasal undifferentiated carcinoma. Mod Pathol. 2019;32(10):1447–59.CrossRefPubMedPubMedCentral
35.
Jp WEIR. Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. The Journal of Strength & Conditioning Research. 2005;19(1):231–40.
36.
Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series B: Statistical Methodology. 1996;58(1):267–88.MathSciNet
37.
Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010;143(3):331–6.CrossRefPubMedPubMedCentral
38.
Apte AP, Iyer A, Crispin-Ortuzar M, Pandya R, van Dijk LV, Spezi E, Thor M, Um H, Veeraraghavan H, Oh JH, et al. Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys. 2018;45(8):3713–20.
39.
Lee M, Lee H, Cheon GJ, Kim HS, Chung HH, Kim JW, Park NH, Song YS. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer. Eur Radiol. 2017;27(1):16–23.CrossRefPubMed
40.
Liu S, Feng Z, Jiang Z, Wen H, Xu J, Pan H, Deng Y, Zhang L, Ju X, Chen X, et al. Prognostic predictive value of preoperative intratumoral 2-deoxy-2-(18F)fluoro-D-glucose uptake heterogeneity in patients with high-grade serous ovarian cancer. Nucl Med Commun. 2018;39(10):928–35.CrossRefPubMed
41.
Vargas HA, Veeraraghavan H, Micco M, Nougaret S, Lakhman Y, Meier AA, Sosa R, Soslow RA, Levine DA, Weigelt B, et al. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol. 2017;27(9):3991–4001.CrossRefPubMedPubMedCentral
42.
Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS. Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI insight. 2016;1(10):e86829.CrossRefPubMedPubMedCentral
43.
Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. The journal of pathology Clinical research. 2016;2(4):247–58.CrossRefPubMedPubMedCentral
44.
Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD, Gilks CB, Köbel M. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 2020;250(3):336–45.CrossRefPubMed
45.
Wall JA, Meza-Perez S, Scalise CB, Katre A, Londoño AI, Turbitt WJ, Randall T, Norian LA, Arend RC. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2021;160(1):285–94.CrossRefPubMed
46.
Qiu D, Cai W, Zhang Z, Li H, Zhou D. High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis. Arch Gynecol Obstet. 2019;299(5):1415–27.CrossRefPubMed
47.
Beer L, Sahin H, Bateman NW, Blazic I, Vargas HA, Veeraraghavan H, Kirby J, Fevrier-Sullivan B, Freymann JB, Jaffe CC, et al. Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. Eur Radiol. 2020;30(8):4306–16.CrossRefPubMedPubMedCentral
48.
49.
Safaie E, Matthews R, Bergamaschi R. PET scan findings can be false positive. Tech Coloproctol. 2015;19(6):329–30.CrossRefPubMed
50.
Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD, Wong KK, Rubello D. The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging. Biomed Pharmacother. 2019;117:109168.CrossRefPubMedPubMedCentral
Metadata
Title
Survival time prediction in patients with high-grade serous ovarian cancer based on 18F-FDG PET/CT- derived inter-tumor heterogeneity metrics
Authors
Dianning He
Xin Zhang
Zhihui Chang
Zhaoyu Liu
Beibei Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12087-y

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis

Study Protocol

Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial

Research

Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma

Research

Mechanism of intestinal microbiota disturbance promoting the occurrence and development of esophageal squamous cell carcinoma——based on microbiomics and metabolomics

Research

Factors associated with recurrence in patients with oral cancer in Mongolia

Research

Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits